The pan-FGFR inhibitor erdafitinib has shown an overall response rate of 40% in bladder cancer patients whose tumors contained FGFR3 point mutations or FGFR2/3 fusions, leading to FDA approval of this drug in locally advanced or metastatic bladder cancer [164]. Here, FGFR2 is linked to urinary bladder carcinoma.